Cytochrome P450 2B6 516G -> T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population
Open Access
- 30 April 2009
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 10 (5), 310-317
- https://doi.org/10.1111/j.1468-1293.2008.00689.x
Abstract
The aim of the study was to characterize the impact of the cytochrome P450 2B6 (CYP2B6), CYP3A4, CYP3A5 and ATP-binding cassette sub-family B member 1 (ABCB1) polymorphisms on nevirapine plasma concentrations. A total of 104 patients (82% male; 26% non-Caucasian) were genotyped for eight single nucleotide polymorphisms at four loci (CYP2B6, CYP3A4, CYP3A5 and MDR1). Nevirapine plasma concentrations were determined using high-performance liquid chromatography. Non-Caucasian ethnicity [5609 ng/mL (n=27) for non-Caucasians vs. 3771 ng/mL (n=77) for Caucasians; P < 0.0001] and CYP2B6 516G -> T [GG, 3574 ng/mL (n=50); GT, 4634 ng/mL (n=50); TT, 8170 ng/mL (n=4); P-analysis of variance (anova)=0.001] were significantly associated with a higher nevirapine trough concentration (C-trough). The latter association was maintained with both 200 mg twice daily (bid) and 400 mg once daily (qd) dosing [GG, 3527 ng/mL (n=30); GT, 4525 ng/mL (n=32); TT, 7020 ng/mL (n=2); P-anova=0.05 and GG, 3645 ng/mL (n=20); GT, 4861 ng/mL (n=17); TT, 9508 ng/mL (n=2); P-anova=0.01, respectively]. In a multivariable analysis, CYP2B6 516G -> T and non-Caucasian ethnicity remained significant predictors of nevirapine C-trough but CYP2B6 516G -> T homozygosity had the greatest effect (108% higher, 46% higher). No associations were found between nevirapine C-trough and the remaining polymorphisms. In this population, both non-Caucasian ethnicity and carriage of the variant allele of CYP2B6 516G -> T were significant predictors of nevirapine C-trough. The association between CYP2B6 516G -> T and higher plasma nevirapine exposure was maintained at both bid and qd dosing.Keywords
This publication has 33 references indexed in Scilit:
- British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008HIV Medicine, 2008
- Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patientsJournal of Antimicrobial Chemotherapy, 2008
- Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV‐infected patients in UgandaHIV Medicine, 2007
- Pharmacogenetics of HIV therapyPharmacogenetics and Genomics, 2006
- Study of the Sequence of Events Involved in Nevirapine-Induced Skin Rash in Brown Norway RatsChemical Research in Toxicology, 2006
- Evidence of an Immune-Mediated Mechanism for an Idiosyncratic Nevirapine-Induced Reaction in the Female Brown Norway RatChemical Research in Toxicology, 2005
- Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivoClinical Pharmacology & Therapeutics, 2005
- Drug-Induced Liver Injury Associated with the Use of Nonnucleoside Reverse-Transcriptase InhibitorsClinical Infectious Diseases, 2004
- Low Nevirapine Plasma Concentrations Predict Virological Failure in an Unselected HIV-1-Infected PopulationClinical Pharmacokinetics, 2003
- Population pharmacokinetics of nevirapine in an unselected cohort of HIV‐1‐infected individualsBritish Journal of Clinical Pharmacology, 2002